tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

PainChek Secures FDA Approval, Unlocking Major US Market

Story Highlights
  • PainChek Ltd’s app is the first FDA-approved device for pain assessment in the US.
  • The FDA approval opens a USD $100 million market opportunity for PainChek in US aged care.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
PainChek Secures FDA Approval, Unlocking Major US Market

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

PainChek Ltd ( (AU:PCK) ) has provided an update.

PainChek Ltd has received a De Novo classification from the FDA for its PainChek Adult App, marking it as the first regulated medical device for pain assessment in the US. This approval opens up a significant market opportunity in the US aged care sector, estimated at over USD $100 million annually, and positions the company for rapid expansion into other segments like home care and hospitals. Strategic partnerships with major healthcare software providers and a strong regulatory landscape further enhance PainChek’s market entry and growth prospects in the US and globally.

More about PainChek Ltd

PainChek Ltd is a company that develops smart device-based applications for pain assessment and monitoring. It operates in the healthcare industry, focusing on providing innovative solutions for pain management, particularly in aged care markets. The company is known for its PainChek Adult App, which is the first regulated medical device of its kind for pain assessment.

Average Trading Volume: 2,783,976

Technical Sentiment Signal: Buy

Current Market Cap: A$165.1M

See more data about PCK stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1